Effects of Dietary Modification Based on Complementary and Alternative Iranian Medicine in Patients with Secondary-Progressive Multiple Sclerosis: A Randomized Controlled Clinical Trial

被引:3
|
作者
Moravejolahkami, Amir Reza [1 ]
Hadi, Saeid [1 ]
Hadi, Vahid [1 ]
Mirghazanfari, Sayid Mahdi [2 ]
Mohajeri, Mohsen [3 ,4 ]
机构
[1] AJA Univ Med Sci, Fac Med, Dept Hlth & Nutr, West Fatemi St, Tehran 1411718541, Iran
[2] AJA Univ Med Sci, Sch Med, Dept Physiol & Iranian Med, West Fatemi St, Tehran 1411718541, Iran
[3] AJA Univ Med Sci, Fac Med, Dept Persian Med, Tehran, Iran
[4] Iran Univ Med Sci, Sch Persian Med, Dept Tradit Med, Tehran, Iran
来源
JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE | 2023年 / 29卷 / 11期
关键词
diet therapy; complementary therapies; Persian medicine; secondary-progressive multiple sclerosis; randomized controlled trial; PRIMROSE OILS INTERVENTION; SUPPLEMENTED HEMP SEED; HOT-NATURE DIET; PERSIAN VERSION; QUESTIONNAIRE; RELIABILITY; THERAPIES; SYMPTOMS; VALIDITY;
D O I
10.1089/jicm.2023.0037
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: To evaluate the efficacy of dietary modifications based on complementary and alternative Iranian medicine (CAIM) in patients with secondary-progressive multiple sclerosis (SPMS).Design: In this randomized controlled trial, 70 SPMS patients were randomized to receive either a moderate-nature diet based on Persian medicine (as intervention) or usual diet plus health-related diet recommendations (as control) for 2 months. Serum high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), Expanded Disability Status Scale (EDSS), Modified Fatigue Impact Scale (MFIS), State-Trait Anxiety Inventory (STAI), Global Pain Scale (GPS), Gastrointestinal Symptom Rating Scale (GSRS), anthropometric measurements, and quality of life (QOL) were assessed at baseline and end of trial. Analysis of covariance was performed, and the results were adjusted for potential confounders using SPSS v.14.Results: All participants completed the study for 2 months. There were significant improvements across the mean changes of hs-CRP (-0.1 +/- 0.2 mg/L for intervention vs. -0.01 +/- 0.13 mg/L for control; p(adjusted) = 0.012), MFIS (-11.0 +/- 11.8 vs. -0.7 +/- 9.9; p(adjusted) <0.001), GSRS (-19.9 +/- 16.3 to 1.2 +/- 17.5; p(adjusted) <0.001), GPS (p(adjusted) = 0.032), and QOL (p(adjusted) <0.05). No significant difference was observed across the ESR, EDSS, STAI, and anthropometric measurements.Conclusion: Dietary modifications based on CAIM may improve inflammation and clinical manifestations in SPMS patients. Nonetheless, further trials are required to confirm these findings.Clinical Trial Registration number: IRCT20181113041641N2.
引用
收藏
页码:747 / 756
页数:10
相关论文
共 50 条
  • [31] Effects of neurodynamic interventions on pain sensitivity and function in patients with multiple sclerosis: a randomized clinical trial
    de Dios Perez-Bruzon, Juan
    Fernandez-de-las-Penas, Cesar
    Cleland, Joshua A.
    Plaza-Manzano, Gustavo
    Ortega-Santiago, Ricardo
    PHYSIOTHERAPY, 2022, 115 : 36 - 45
  • [32] Impact of nutrition counseling on anthropometry and dietary intake of multiple sclerosis patients at Kasr Alainy Multiple Sclerosis Unit, Cairo, Egypt 2019-2020: randomized controlled clinical trial
    Afifi, Zeinab
    Hassan, Amr
    Abdelrahman, Nebal
    El Sayed, Asmaa
    Salem, Marwa
    ARCHIVES OF PUBLIC HEALTH, 2023, 81 (01)
  • [33] The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial
    Carletto, Sara
    Borghi, Martina
    Francone, Diana
    Scavelli, Francesco
    Bertino, Gabriella
    Cavallo, Marco
    Malucchi, Simona
    Bertolotto, Antonio
    Oliva, Francesco
    Ostacoli, Luca
    BMC NEUROLOGY, 2016, 16
  • [34] The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial
    Sara Carletto
    Martina Borghi
    Diana Francone
    Francesco Scavelli
    Gabriella Bertino
    Marco Cavallo
    Simona Malucchi
    Antonio Bertolotto
    Francesco Oliva
    Luca Ostacoli
    BMC Neurology, 16
  • [35] Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): Results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial
    Steiner, Deborah
    Arnold, Douglas
    Freedman, Mark
    Goldman, Myla
    Hartung, Hans-Peter
    Havrdova, Eva
    Jeffery, Douglas
    Kapoor, Raj
    Miller, Aaron
    Sellebjerg, Finn
    Amarante, Diogo
    Cadavid, Diego
    Yu, Bei
    Forrestal, Fiona
    Liu, Kezhen
    NEUROLOGY, 2016, 87 (02) : E22 - E22
  • [36] Subgroup analyses of natalizumab treatment response in ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial in patients with secondary progressive multiple sclerosis (SPMS).
    Kapoor, R.
    Steiner, D.
    Miller, A.
    Giovannoni, G.
    Cohan, S.
    Gold, R.
    Rog, D.
    Ho, P. -R.
    Elkins, J.
    Li, H.
    Amarante, D.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 874 - 875
  • [37] Effects of Acupuncture on Cognitive Functions in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial
    Khodaie, Faezeh
    Saeedi, Roghayyeh
    Soleimany, Ghazaleh
    Sahraian, Mohammad Ali
    Kazemi, Amir Hooman
    Moghadasi, Abdorreza Naser
    Zhao, Bai-xiao
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2025,
  • [38] T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial
    Karussis, Dimitrios
    Shor, Hagai
    Yachnin, Julia
    Lanxner, Naama
    Amiel, Merav
    Baruch, Keren
    Keren-Zur, Yael
    Haviv, Ofra
    Filippi, Massimo
    Petrou, Panayiota
    Hajag, Shalom
    Vourka-Karussis, Urania
    Vaknin-Dembinsky, Adi
    Khoury, Salim
    Abramsky, Oded
    Atlan, Henri
    Cohen, Irun R.
    Abulafia-Lapid, Rivka
    PLOS ONE, 2012, 7 (12):
  • [39] Cycling in primary progressive multiple sclerosis (CYPRO): study protocol for a randomized controlled superiority trial evaluating the effects of high-intensity interval training in persons with primary progressive multiple sclerosis
    Kupjetz, Marie
    Joisten, Niklas
    Rademacher, Annette
    Gonzenbach, Roman
    Bansi, Jens
    Zimmer, Philipp
    BMC NEUROLOGY, 2023, 23 (01)
  • [40] Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study
    Fernandez, Oscar
    Izquierdo, Guillermo
    Fernandez, Victoria
    Leyva, Laura
    Reyes, Virginia
    Guerrero, Miguel
    Leon, Antonio
    Arnaiz, Carlos
    Navarro, Guillermo
    Dolores Paramo, Maria
    De la Cuesta, Antonio
    Soria, Bernet
    Hmadcha, Abdelkrim
    Pozo, David
    Fernandez-Montesinos, Rafael
    Leal, Maria
    Ochotorena, Itziar
    Galvez, Patricia
    Angeles Geniz, Maria
    Javier Baron, Francisco
    Mata, Rosario
    Medina, Cristina
    Caparros-Escudero, Carlos
    Cardesa, Ana
    Cuende, Natividad
    PLOS ONE, 2018, 13 (05):